Evidence map›Paper›PMID 35117591›Full record

ArticleTranslational cancer research2020

The prognostic roles of red blood cell-associated indicators in patients with resectable gastric cancers.

Meng-Ting Cui, Zhan-Wen Liang, Yi-Zhang Sun, Jing Wu, Hong Lu, Wen-Jie Wang, Meng-Dan Xu, Min Jiang, Wei Li, Jun Qian and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Meng-Ting Cui *Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Zhan-Wen Liang *Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Yi-Zhang Sun *Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Jing WuDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Hong LuDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Wen-Jie WangDepartment of Radio-Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou 215001, China.
Meng-Dan XuDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Min JiangDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Wei LiDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Jun QianDepartment of Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou 215001, China.
Wei-Ming DuanDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer (GC) is one of the leading causes of cancer-related death worldwide. This study was designed to investigate the prognostic values of red blood cell (RBC)-associated indicators, including RBC, hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and RBC distribution width (RDW) in resectable GC patients.

methodsIn this retrospective study, a total of 104 pathologically confirmed GC patients were recruited. These cases were divided into two groups according to the median values of pretreatment RBC, HGB, HCT, MCV, MCH, MCHC, or RDW. To evaluate the changes in RBC-associated indicators values after treatment, we introduced the concept of post-/pre-treatment ratios (≤1 suggested RBC, HGB, HCT, MCV, MCH, MCHC, or RDW values were not increased after therapy, while >1 represented those in increased levels).

resultsThe lower pretreatment MCHC levels were correlated with worse overall survival (OS), while pretreatment levels of RBC, HGB, HCT, MCV, MCH, or RDW were not. The whole course of treatment (surgery plus adjuvant chemotherapy) significantly decreased the values of MCHC, and increased the values of MCV and RDW, whereas it had no obvious effects on the values of RBC, HGB, HCT, or MCH. Patients with post-/pre-treatment MCV ratio >1 had an increased survival ratio. Meanwhile, post-/pre-treatment RBC, HGB, HCT, MCH, MCHC, or RDW ratios were not correlated with outcomes. Multivariate Cox regression analysis revealed that the American Joint Committee on Cancer (AJCC) stage (III), and lower pretreatment MCHC levels were independent risk factors affecting OS. The receiver operating characteristic (ROC) curve analysis showed that an MCHC value of 341.98 g/L was the optimal cutoff value for prognosis, with a sensitivity of 58.3% and a specificity of 75.0%.

conclusionsPretreatment MCHC levels could become a potential prognostic factor for resectable GC.

Indexed as

Gastric cancer (GC)prognosisred blood cell-associated indicators (RBC-associated indicators)

Identifiers

PMID35117591
PMCPMC8797860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.